Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08QGT
|
|||
| Former ID |
DCL001088
|
|||
| Drug Name |
GDC0941
|
|||
| Synonyms |
Pictilisib; GDC-0941; 957054-30-7; PICTILISIB; Pictrelisib; GDC 0941; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; UNII-ICY00EMP8P; ICY00EMP8P; Pictilisib (GDC-0941); CHEBI:65326; AK-40872; Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-; GD9; GDC-0941, GDC0941; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2 | [2], [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [2], [3] | ||
| Company |
Genentech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27N7O3S2
|
|||
| Canonical SMILES |
CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6
|
|||
| InChI |
1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
|
|||
| InChIKey |
LHNIIDJUOCFXAP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 957054-30-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
29212926, 49786957, 54248659, 56374172, 85756855, 87225804, 99436963, 103605815, 103905592, 124756973, 124898667, 125163778, 126583893, 126644602, 126666983, 126724369, 131331324, 131465130, 134339479, 134964407, 135256495, 135264679, 135626907, 135631960, 135684972, 135685275, 135685279, 135685283, 135686120, 135686121, 135686142, 135686143, 135698921, 135727434, 136920330, 137244615, 137275833, 140991552, 143498831, 144116006, 152105922, 152240252, 152258791, 152344010, 160644992, 160647642, 160778578, 160826754, 162011380, 162037413
|
|||
| ChEBI ID |
CHEBI:65326
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in P... J Clin Oncol. 2016 Jun 10;34(17):1987-94. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5682). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027517) | |||
| REF 4 | Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. | |||
| REF 5 | The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.